Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Severe active rheumatoid arthritis Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient, AND Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; OR Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate, AND The treatment must be initiated by a physician.
Severe active psoriatic arthritis Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient, AND Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; OR Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate, AND The treatment must be initiated by a physician.
“The anti-proliferative activity is reversed by the addition of uridine to the cell culture, indicating that A771726 acts at the level of the pyrimidine biosynthesis pathway. Binding studies using radio-labelled ligand demonstrate that the active metabolite binds to and inhibits the human enzyme dihydroorotate dehydrogenase (DHODH, an enzyme involved in de novo pyrimidine synthesis).”
“Due to the very long half-life of A771726 (~ 2 weeks), a loading dose of 100 mg leflunomide for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state levels of A771726.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“In vitro studies indicate that A771726 inhibits cytochrome P450 2C9 (CYP2C9) activity.”